1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNational Organization for Rare Disorders (NORD) Seed Grant Program is sponsored by National Organization for Rare Disorders (NORD). Provides early-stage funding to accelerate research for rare diseases.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
National Organization for Rare Disorders (NORD) Announces Annual Seed Grant RFPs Totaling $245,000 to Accelerate Research for Five Rare Diseases QUINCY, Mass. , Aug. 13, 2025 /PRNewswire/ -- The National Organization for Rare Disorders (NORD ® ), a leading national nonprofit serving more than 30 million Americans with rare diseases, announced five new requests for proposal (RFP) totaling $245,000 in seed grant funding.
These grants were funded by the Appendix Cancer/Pseudomyxoma Peritonei Research Foundation; the Peutz-Jeghers Syndrome community; the Epidermodysplasia Verruciformis community; the Pseudomyxoma Peritonei community; and Dylan's Rare Chromosome Dream Team and the Partial Trisomy 6q community.
The grants are part of NORD's Rare Disease Research Grant Program , which provides essential early-stage funding to jumpstart promising investigations and accelerate the development of potential treatments for rare diseases where therapeutic options are limited or nonexistent.
This cycle, NORD is seeking proposals for the following rare diseases: Chromosome 6, Partial Trisomy 6q – An extremely rare chromosomal disorder in which a portion of the 6th chromosome (6q) is present three times (trisomy) rather than twice in cells of the body.
Epidermodysplasia Verruciformis (EV) – A rare genetic genodermatosis characterized by a compromised immunologic ability to defend against and eradicate certain types of human papillomavirus (HPV) leading to polymorphous cutaneous lesions and high risk of developing non-melanoma skin cancer.
Peutz-Jeghers Syndrome (PJS) – A rare genetic condition characterized by the development of benign polyps in the stomach and the intestines (gastrointestinal tract) and by distinctive dark spots on the skin and mucous membranes. Pseudomyxoma Peritonei (PMP) – A rare malignant growth characterized by the progressive accumulation of mucus-secreting (mucinous) tumor cells within the abdomen and pelvis.
Appendix Cancer/Pseudomyxoma Peritonei (ACPMP) – An extremely rare cancer of the appendix that typically starts in the appendix and frequently spreads to the abdominal cavity, which can lead to either a build-up of mucinous fluid in the abdomen known as pseudomyxoma peritonei or a condition referred to as peritoneal carcinomatosis.
Recipients will be awarded to qualified researchers to initiate small scientific research studies or clinical trials with the potential to attract larger funding from agencies like the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), or corporate sponsors.
This early support helps expand promising early-stage projects into comprehensive, multi-phase studies that can lead to new treatments for rare and complex diseases. Applications will be reviewed by NORD's Medical Advisory Committee, a panel of volunteer rare disease medical experts. The application period opens on Aug.
13, 2025 , and closes on Oct. 12, 2025 ( 11:59 p. m.
PT ). Researchers at accredited academic institutions, hospitals and nonprofit research centers, and early-career investigators are encouraged to apply. Learn more and view application instructions here .
About NORD's Rare Disease Research Grant Program Since 1989, NORD has awarded more than $9 million in research grants to advance scientific discovery for rare diseases that lack treatment and research funding.
With fewer than 5% of the approximately 10,000 known rare diseases having an FDA-approved therapy, and the cost to develop a prescriptive medication costing millions of dollars, early-stage funding plays a critical role in unlocking progress. NORD's grant program has jump-started critical rare disease research, supported numerous peer-reviewed publications, and contributed to the development of two FDA-approved treatments.
About the National Organization for Rare Disorders Founded in 1983, the National Organization for Rare Disorders (NORD ® ) is a leading independent, nonpartisan, nonprofit patient advocacy organization dedicated to improving the health and lives of over 30 million Americans living with rare diseases.
In partnership with more than 350 disease-specific member patient organizations, NORD drives progress in rare disease research, care, and policy. Learn more at https://rarediseases.
org/ SOURCE National Organization for Rare Disorders (NORD®) more press release views with National Organization for Rare Disorders Expands Rare Disease Centers of Excellence Network The National Organization for Rare Disorders (NORD®) today announced three new additions to its NORD Rare Disease Centers of Excellence (RD CoE)...
National Organization for Rare Disorders Appoints Kathryn Lowell as Executive Vice President, Government Affairs The National Organization for Rare Disorders (NORD®), representing the more than 30 million Americans living with rare diseases, today announced the... More Releases From This Source Household, Consumer & Cosmetics News Releases in Similar Topics
According to the current listing, eligibility includes: Researchers and institutions focusing on rare diseases. Confirm the full requirements in the official notice before applying.
The current listing shows totaling $245,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
National Organization for Rare Disorders (NORD) Seed Grant Program is funded by National Organization for Rare Disorders (NORD). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Anthropic is giving rare-disease researchers and early-stage biotechs up to $50,000 in Claude API credits over six months — not cash, but compute. Here is how the two-track program works, who is eligible, what the credits can and cannot do, and how it fits a fast-growing new category: the compute-as-grant model reshaping how AI-for-science actually gets funded.
Read articleThe Department of Energy's Office of Critical Minerals and Energy Innovation is spending to break America's 95% dependence on foreign rare earths. The strategy is unusual: recover critical materials from the waste streams of coal plants, smelters, and refineries that already exist. Here is the full funding architecture — the $75M just awarded, the $500M battery-materials round, the $1B pipeline behind them — and how an industrial operator should position for what comes next.
Read articleOn June 2, 2026, the Department of Energy's Office of Critical Minerals and Energy Innovation selected two demonstration-scale facilities — Phoenix Tailings (with MIT and the University of Minnesota) for $66 million, and the Colorado School of Mines (with ElementUSA, PNNL, Principal Mineral, and Rare Earth Technologies Inc.) for the balance — under the Rare Earth Elements Demonstration Facility Program. Both projects pull rare earths from industrial waste — red mud at the Gramercy refinery in Louisiana, and a mix of mine and refining tailings elsewhere. Here is what the selections tell researchers, small businesses, and downstream magnet customers about where DOE thinks the chokepoint actually is, and what to do before the next demonstration-scale solicitation opens.
Read article